JP2003521437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003521437A5 JP2003521437A5 JP2000516658A JP2000516658A JP2003521437A5 JP 2003521437 A5 JP2003521437 A5 JP 2003521437A5 JP 2000516658 A JP2000516658 A JP 2000516658A JP 2000516658 A JP2000516658 A JP 2000516658A JP 2003521437 A5 JP2003521437 A5 JP 2003521437A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- renin
- pharmaceutical composition
- composition according
- angiotensin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 description 20
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 230000036454 renin-angiotensin system Effects 0.000 description 13
- 239000005541 ACE inhibitor Substances 0.000 description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 7
- 229940044551 receptor antagonist Drugs 0.000 description 7
- 229960003401 ramipril Drugs 0.000 description 6
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 6
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 6
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 5
- 206010006895 Cachexia Diseases 0.000 description 5
- 108010007859 Lisinopril Proteins 0.000 description 5
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 5
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 5
- 229960002490 fosinopril Drugs 0.000 description 5
- 229960002394 lisinopril Drugs 0.000 description 5
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 5
- 229960005170 moexipril Drugs 0.000 description 5
- 229960002582 perindopril Drugs 0.000 description 5
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 5
- 229960001455 quinapril Drugs 0.000 description 5
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 5
- 229960002051 trandolapril Drugs 0.000 description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
- 239000002083 C09CA01 - Losartan Substances 0.000 description 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 4
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 4
- 108010061435 Enalapril Proteins 0.000 description 4
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960005025 cilazapril Drugs 0.000 description 4
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 4
- 229960000873 enalapril Drugs 0.000 description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
- 229960001195 imidapril Drugs 0.000 description 4
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229960002198 irbesartan Drugs 0.000 description 4
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 4
- 229960004773 losartan Drugs 0.000 description 4
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 4
- 229960004699 valsartan Drugs 0.000 description 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 4
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960005187 telmisartan Drugs 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
- 102000002397 Kinins Human genes 0.000 description 2
- 108010093008 Kinins Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229950007884 alacepril Drugs 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- 229960000932 candesartan Drugs 0.000 description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960005227 delapril Drugs 0.000 description 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 2
- 239000002792 enkephalinase inhibitor Substances 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002461 renin inhibitor Substances 0.000 description 2
- 229940086526 renin-inhibitors Drugs 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229960002909 spirapril Drugs 0.000 description 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 2
- 108700035424 spirapril Proteins 0.000 description 2
- 229960000651 tasosartan Drugs 0.000 description 2
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 2
- 229960004084 temocapril Drugs 0.000 description 2
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 229950005749 ceronapril Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9722026.3 | 1997-10-17 | ||
| GBGB9722026.3A GB9722026D0 (en) | 1997-10-17 | 1997-10-17 | Use of compounds |
| GB9810855.8 | 1998-05-20 | ||
| GBGB9810855.8A GB9810855D0 (en) | 1998-05-20 | 1998-05-20 | Use of compounds |
| PCT/GB1998/003122 WO1999020260A2 (en) | 1997-10-17 | 1998-10-19 | The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009166483A Division JP2009242426A (ja) | 1997-10-17 | 2009-07-15 | レニン−アンジオテンシン系の阻害剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003521437A JP2003521437A (ja) | 2003-07-15 |
| JP2003521437A5 true JP2003521437A5 (https=) | 2006-01-05 |
| JP5187991B2 JP5187991B2 (ja) | 2013-04-24 |
Family
ID=26312447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000516658A Expired - Fee Related JP5187991B2 (ja) | 1997-10-17 | 1998-10-19 | レニン−アンジオテンシン系の阻害剤の使用 |
| JP2009166483A Pending JP2009242426A (ja) | 1997-10-17 | 2009-07-15 | レニン−アンジオテンシン系の阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009166483A Pending JP2009242426A (ja) | 1997-10-17 | 2009-07-15 | レニン−アンジオテンシン系の阻害剤の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US7071183B2 (https=) |
| EP (4) | EP1559424A3 (https=) |
| JP (2) | JP5187991B2 (https=) |
| KR (3) | KR100523112B1 (https=) |
| CN (1) | CN1123342C (https=) |
| AP (1) | AP1300A (https=) |
| AT (2) | ATE294579T1 (https=) |
| AU (1) | AU742506B2 (https=) |
| CA (2) | CA2677910C (https=) |
| CY (1) | CY1106813T1 (https=) |
| DE (2) | DE69830069T3 (https=) |
| DK (2) | DK1023067T4 (https=) |
| ES (2) | ES2238770T5 (https=) |
| HU (2) | HUP0003982A3 (https=) |
| NO (1) | NO326231B1 (https=) |
| PL (2) | PL197164B1 (https=) |
| PT (2) | PT1498124E (https=) |
| UY (2) | UY25972A1 (https=) |
| WO (1) | WO1999020260A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| DK1216038T3 (da) * | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| AU4686401A (en) * | 2000-04-10 | 2001-10-23 | Yuichi Ishida | Hypotensors |
| EP1383885A4 (en) * | 2001-04-04 | 2005-11-30 | American Diagnostica Inc | METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF |
| GB0119460D0 (en) * | 2001-08-09 | 2001-10-03 | Ark Therapeutics Ltd | The use of inhibitors of the renin-angiotensin system |
| MXPA04004844A (es) * | 2001-11-23 | 2004-07-30 | Solvay Pharm Gmbh | Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular. |
| EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
| EP2204455A1 (en) | 2002-08-29 | 2010-07-07 | American Diagnostica, Inc. | Diagnostic assay for thrombin-activatable fibrinolysis inhibitor (TAFI) |
| EP1600166A4 (en) * | 2003-01-17 | 2008-02-27 | Takeda Pharmaceutical | SKELETAL MUSCLE PROTECTIVE AGENT |
| WO2005084648A1 (en) * | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising candesartan cilexetil |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| WO2006009325A1 (ja) * | 2004-07-23 | 2006-01-26 | Ono Pharmaceutical Co., Ltd. | メタロプロテアーゼ阻害剤 |
| WO2006102476A2 (en) * | 2005-03-21 | 2006-09-28 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
| AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
| CN101951921A (zh) * | 2007-09-17 | 2011-01-19 | 比奥尼里斯有限责任公司 | 用于治疗恶病质的方法和手段 |
| RU2393857C2 (ru) * | 2008-05-12 | 2010-07-10 | Государственное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию | Лекарственное средство, оказывающее противосудорожное и антигипоксическое действие |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| WO2012135597A2 (en) | 2011-03-30 | 2012-10-04 | The Johns Hopkins University | Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair |
| KR20130074808A (ko) * | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
| EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
| WO2015108342A1 (ko) * | 2014-01-14 | 2015-07-23 | 최원철 | 루테리알의 형태특성을 이용한 암 예방제 또는 항암제의 스크리닝 방법 |
| JP2016183174A (ja) * | 2016-05-12 | 2016-10-20 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 双極性トランスカロテノイド塩及びそれらの使用 |
| WO2019241590A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition |
| DE202023100085U1 (de) | 2023-01-09 | 2023-02-03 | Sundararajan Gothandam | Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2655989B1 (fr) * | 1989-12-20 | 1992-02-28 | Adir | Nouveaux derives d'amino-acides substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5049553A (en) * | 1990-01-04 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Method for preventing or treating symptoms resulting from closed head injuries employing an ace inhibitor |
| GB2241890A (en) | 1990-03-12 | 1991-09-18 | Squibb & Sons Inc | Preventing onset of or treating protein catabolism using an ace inhibitor |
| US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| CA2048699A1 (en) * | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Method for preventing or treating cerebro-vascular disease employing ceronapril |
| CA2052014A1 (en) | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| TW197945B (https=) * | 1990-11-27 | 1993-01-11 | Hoechst Ag | |
| FI905896A7 (fi) * | 1990-11-29 | 1992-05-30 | Valmet Paper Machinery Inc | Formningsgapsarrangemang i en dubbelviraformare av en pappersmaskin. |
| GB9027199D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
| GB9108811D0 (en) * | 1991-04-24 | 1991-06-12 | Erba Carlo Spa | N-imidazolyl derivatives of substituted indole |
| WO1993018794A1 (en) | 1992-03-26 | 1993-09-30 | Gensia, Inc. | In vivo peptide therapy |
| US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| US5374643A (en) * | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
| US5464854A (en) * | 1993-11-11 | 1995-11-07 | Depadova; Anathony S. | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
| CA2140722A1 (en) * | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US5468757A (en) * | 1994-01-31 | 1995-11-21 | Eli Lilly And Company | 6-azaindole thromboxane synthase inhibitors |
| US5550118A (en) * | 1994-01-31 | 1996-08-27 | Eli Lilly And Company | Polyhydronorharman synthase inhibitors |
| DE4410997A1 (de) * | 1994-03-30 | 1995-10-26 | Isis Pharma Gmbh | Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen |
| DE4420102A1 (de) | 1994-06-09 | 1995-12-14 | Asta Medica Ag | Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
| US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| US5645839A (en) * | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| TW356468B (en) * | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
| AU7213296A (en) * | 1995-10-06 | 1997-04-30 | Ciba-Geigy Ag | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| EP0868179A4 (en) * | 1995-12-12 | 2002-01-30 | Merck & Co Inc | NEW USE OF LOSARTAN |
| US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
| US6420412B2 (en) * | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| DE19614542A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19614533A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
| US20040122096A1 (en) * | 1996-06-03 | 2004-06-24 | Hoechst Aktiengesellschaft | Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids |
| DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
| JP2002511837A (ja) | 1996-09-10 | 2002-04-16 | メデイノックス，インコーポレイテッド | ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用 |
| US6008221A (en) | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
| PL334014A1 (en) * | 1996-12-18 | 2000-01-31 | Basf Ag | Heterocyclic derivatives of carboxylic acids, their preduction and application as antagonists of endothelin receptors |
| EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6197505B1 (en) * | 1997-04-04 | 2001-03-06 | Pyrosequencing Ab | Methods for assessing cardiovascular status and compositions for use thereof |
| US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| DK1216038T3 (da) * | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
-
1998
- 1998-10-19 KR KR10-2000-7004109A patent/KR100523112B1/ko not_active Expired - Fee Related
- 1998-10-19 CA CA2677910A patent/CA2677910C/en not_active Expired - Lifetime
- 1998-10-19 DK DK98947698.1T patent/DK1023067T4/da active
- 1998-10-19 HU HU0003982A patent/HUP0003982A3/hu unknown
- 1998-10-19 KR KR1020007004104A patent/KR20010031177A/ko not_active Ceased
- 1998-10-19 WO PCT/GB1998/003122 patent/WO1999020260A2/en not_active Ceased
- 1998-10-19 CA CA2306216A patent/CA2306216C/en not_active Expired - Fee Related
- 1998-10-19 PT PT04021889T patent/PT1498124E/pt unknown
- 1998-10-19 DE DE69830069T patent/DE69830069T3/de not_active Expired - Lifetime
- 1998-10-19 DK DK04021889T patent/DK1498124T3/da active
- 1998-10-19 EP EP05009398A patent/EP1559424A3/en not_active Withdrawn
- 1998-10-19 EP EP04021889A patent/EP1498124B1/en not_active Revoked
- 1998-10-19 EP EP20070102160 patent/EP1776954A3/en not_active Ceased
- 1998-10-19 PL PL377096A patent/PL197164B1/pl unknown
- 1998-10-19 PL PL340838A patent/PL193215B1/pl not_active IP Right Cessation
- 1998-10-19 AP APAP/P/2000/001796A patent/AP1300A/en active
- 1998-10-19 ES ES98947698T patent/ES2238770T5/es not_active Expired - Lifetime
- 1998-10-19 AT AT98947698T patent/ATE294579T1/de active
- 1998-10-19 CN CN98811314A patent/CN1123342C/zh not_active Expired - Fee Related
- 1998-10-19 AT AT04021889T patent/ATE366110T1/de active
- 1998-10-19 DE DE69838042T patent/DE69838042T2/de not_active Expired - Lifetime
- 1998-10-19 KR KR1020057013064A patent/KR100572080B1/ko not_active Expired - Fee Related
- 1998-10-19 ES ES04021889T patent/ES2287617T3/es not_active Expired - Lifetime
- 1998-10-19 PT PT98947698T patent/PT1023067E/pt unknown
- 1998-10-19 EP EP98947698A patent/EP1023067B2/en not_active Expired - Lifetime
- 1998-10-19 JP JP2000516658A patent/JP5187991B2/ja not_active Expired - Fee Related
- 1998-10-19 AU AU94533/98A patent/AU742506B2/en not_active Ceased
- 1998-10-19 HU HU0900792A patent/HU0900792D0/hu not_active Application Discontinuation
-
2000
- 2000-01-17 UY UY25972A patent/UY25972A1/es not_active Application Discontinuation
- 2000-01-17 UY UY25971A patent/UY25971A1/es not_active IP Right Cessation
- 2000-04-14 NO NO20001979A patent/NO326231B1/no not_active IP Right Cessation
-
2002
- 2002-07-26 US US10/206,659 patent/US7071183B2/en not_active Expired - Fee Related
-
2005
- 2005-04-29 US US11/118,824 patent/US20050192326A1/en not_active Abandoned
- 2005-04-29 US US11/119,181 patent/US7998953B2/en not_active Expired - Fee Related
-
2006
- 2006-05-25 US US11/441,648 patent/US8003679B2/en not_active Expired - Fee Related
-
2007
- 2007-08-09 CY CY20071101077T patent/CY1106813T1/el unknown
-
2008
- 2008-09-05 US US12/205,090 patent/US20090069348A1/en not_active Abandoned
-
2009
- 2009-07-15 JP JP2009166483A patent/JP2009242426A/ja active Pending
-
2012
- 2012-01-30 US US13/360,895 patent/US8604070B2/en not_active Expired - Fee Related
-
2013
- 2013-10-21 US US14/058,689 patent/US20140045907A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003521437A5 (https=) | ||
| CA2306216A1 (en) | The use of inhibitors of the renin-angiotensin system for the treatment of cachexia and wasting | |
| Stanton | Therapeutic potential of renin inhibitors in the management of cardiovascular disorders | |
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| Stanton | Potential of renin inhibition in cardiovascular disease | |
| JP2003527325A5 (https=) | ||
| PE20020229A1 (es) | COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE | |
| FI4076652T3 (fi) | Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä | |
| RU2002107985A (ru) | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений | |
| JP2004513920A5 (https=) | ||
| NZ701609A (en) | Liquid formulation comprising propylene glycol and an inodilator | |
| WO2001015674A3 (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events | |
| RU2014110401A (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
| JP2003508426A5 (https=) | ||
| WO2006086456A3 (en) | Combination of organic compounds | |
| RU2017104111A (ru) | Ингибиторы внешнего медуллярного калиевого канала | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| Mollace et al. | Modulation of RAAS-natriuretic peptides in the treatment of HF: old guys and newcomers | |
| Buczko et al. | -Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. | |
| RU2017104110A (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
| JP2001501908A (ja) | 消化不良症候の治療のためのａｃｅ阻害剤の新規な医療への使用 | |
| CA2304712C (en) | Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation | |
| RU2006135205A (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
| AR068814A1 (es) | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso | |
| Rivoli et al. | Pharmacological effects of RAAS blockade in ischemic nephropathy |